Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK Biologicals' investigational vaccine GSK2590066A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval. |
| Group B | EXPERIMENTAL | Subjects will receive 2 doses of a formulation of GSK2592984A vaccine at a 21-day interval. |
| Group C | PLACEBO_COMPARATOR | Subjects will receive 2 doses of a placebo at a 21-day interval. |
| Group D | EXPERIMENTAL | Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval. |
| Group E | EXPERIMENTAL | Subjects will receive 2 doses of a formulation of GSK2340274A vaccine at a 21-day interval. |
| Group F | EXPERIMENTAL | Subjects will receive 2 doses of a formulation of GSK2340273A vaccine at a 21-day interval. |
| Name | Type | Description |
|---|---|---|
| GSK Biologicals' investigational vaccine GSK2590066A | BIOLOGICAL | Intramuscular injection, two doses |
| GSK Biologicals' investigational vaccine GSK2592984A | BIOLOGICAL | Intramuscular injection, two doses |
| GSK Biologicals' investigational vaccine GSK2340274A | BIOLOGICAL | Intramuscular injection, two doses |
| GSK Biologicals' investigational vaccine GSK2340273A | BIOLOGICAL | Intramuscular injection, two doses |
| Placebo | OTHER | Intramuscular injection, two doses |
Inclusion Criteria: * Subjects who the investigator believes can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject. * Male and female adults, 18-49 years of age at the time of the first vaccination. * Satisfactory baseline medical assessment...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | Cell-based Trivalent Split Influenza Virus Vaccine, Egg-based Trivalent Split Influenza Virus Vaccine |
GSK2590066A is an investigational vaccine developed by GSK plc for influenza. It is a Phase 1 candidate studied in healthy adults aged 18 to 49 years. The vaccine is not approved and remains in clinical development.
GSK2590066A is being studied for the prevention of influenza, specifically pandemic influenza. Its only recorded clinical trial enrolled healthy adult volunteers aged 18 to 49 years in the United States. The vaccine is investigational and has not been approved for use.
GSK2590066A is developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 1 trial of the vaccine. GSK Biologicals is the name associated with this investigational influenza vaccine program.
GSK2590066A is in Phase 1 clinical development. Its single recorded trial, NCT01236040, has been completed. The vaccine is investigational and has not been approved by the FDA or any other regulator based on the available information.
GSK2590066A has been studied in one clinical trial, NCT01236040, titled Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old. The Phase 1 trial was completed, enrolled 521 participants, was randomized, double blind, and placebo controlled, and took place in the United States.
Yes, GSK2590066A is a vaccine candidate being developed for influenza. It was evaluated in a Phase 1 trial that measured immunogenicity and safety in healthy adults aged 18 to 49 years. The trial was randomized, double blind, and placebo controlled, with 521 participants enrolled.